Literature DB >> 12649432

Noncovalent scFv multimers of tumor-targeting anti-Lewis(y) hu3S193 humanized antibody.

Barbara E Power1, Larissa Doughty, Deborah R Shapira, John E Burns, Ann M Bayly, Joanne M Caine, Zhanqi Liu, Andrew M Scott, Peter J Hudson, Alexander A Kortt.   

Abstract

Single-chain variable fragments (scFvs) of anti-Lewis(y) hu3S193 humanized antibody were constructed by joining the V(H) and V(L) domains with either +2 residues, +1 residue, or by directly linking the domains. In addition two constructs were synthesized in which one or two C-terminal residues of the V(H) domain were removed (-1 residue, -2 residue) and then joined directly to the V(L) domain. An scFv construct in the reverse orientation with the V(L) joined directly to the V(H) domain was also synthesized. Upon transformation into Escherichia coli all scFv constructs expressed active protein. Binding activity, multimeric status, and multivalent properties were assessed by flow cytometry, size exclusion chromatography, and biosensor analysis. The results for hu3S193 scFvs are consistent with the paradigm that scFvs with a linker of +3 residues or more associate to form a non-covalent dimer, and those with a shorter linker or directly linked associate predominantly to form a non-covalent trimer and tetramer that are in equilibrium. While the association of V domains to form either a dimer or trimer/tetramer is governed by the length of the linker, the stability of the trimer/tetramer in the equilibrium mixture is dependent on the affinity of the interaction of the individual V domains to associate to form the larger Fv module.

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 12649432      PMCID: PMC2323837          DOI: 10.1110/ps.0228503

Source DB:  PubMed          Journal:  Protein Sci        ISSN: 0961-8368            Impact factor:   6.725


  33 in total

1.  Kabat Database and its applications: future directions.

Authors:  G Johnson; T T Wu
Journal:  Nucleic Acids Res       Date:  2001-01-01       Impact factor: 16.971

2.  Tumor targeting of mono-, di-, and tetravalent anti-p185(HER-2) miniantibodies multimerized by self-associating peptides.

Authors:  J Willuda; S Kubetzko; R Waibel; P A Schubiger; U Zangemeister-Wittke; A Plückthun
Journal:  J Biol Chem       Date:  2001-01-22       Impact factor: 5.157

3.  ScFv multimers of the anti-neuraminidase antibody NC10: shortening of the linker in single-chain Fv fragment assembled in V(L) to V(H) orientation drives the formation of dimers, trimers, tetramers and higher molecular mass multimers.

Authors:  O Dolezal; L A Pearce; L J Lawrence; A J McCoy; P J Hudson; A A Kortt
Journal:  Protein Eng       Date:  2000-08

4.  Delivery of the alpha-emitting radioisotope bismuth-213 to solid tumors via single-chain Fv and diabody molecules.

Authors:  G P Adams; C C Shaller; L L Chappell; C Wu; E M Horak; H H Simmons; S Litwin; J D Marks; L M Weiner; M W Brechbiel
Journal:  Nucl Med Biol       Date:  2000-05       Impact factor: 2.408

5.  Tumor targeting of radiometal labeled anti-CEA recombinant T84.66 diabody and t84.66 minibody: comparison to radioiodinated fragments.

Authors:  P J Yazaki; A M Wu; S W Tsai; L E Williams; D N Ikler; J Y Wong; J E Shively; A A Raubitschek
Journal:  Bioconjug Chem       Date:  2001 Mar-Apr       Impact factor: 4.774

Review 6.  Generating improved single-chain Fv molecules for tumor targeting.

Authors:  G P Adams; R Schier
Journal:  J Immunol Methods       Date:  1999-12-10       Impact factor: 2.303

7.  Biodistribution properties of (111)indium-labeled C-functionalized trans-cyclohexyl diethylenetriaminepentaacetic acid humanized 3S193 diabody and F(ab')(2) constructs in a breast carcinoma xenograft model.

Authors:  K Tahtis; F T Lee; F E Smyth; B E Power; C Renner; M W Brechbiel; L J Old; P J Hudson; A M Scott
Journal:  Clin Cancer Res       Date:  2001-04       Impact factor: 12.531

8.  Radioimmunotherapy of human colon cancer xenografts using a dimeric single-chain Fv antibody construct.

Authors:  G Pavlinkova; B J Booth; S K Batra; D Colcher
Journal:  Clin Cancer Res       Date:  1999-09       Impact factor: 12.531

9.  Construction, expression and characterisation of a single-chain diabody derived from a humanised anti-Lewis Y cancer targeting antibody using a heat-inducible bacterial secretion vector.

Authors:  B E Power; J M Caine; J E Burns; D R Shapira; M K Hattarki; K Tahtis; F T Lee; F E Smyth; A M Scott; A A Kortt; P J Hudson
Journal:  Cancer Immunol Immunother       Date:  2001-07       Impact factor: 6.968

10.  Synthesis of high avidity antibody fragments (scFv multimers) for cancer imaging.

Authors:  B E Power; P J Hudson
Journal:  J Immunol Methods       Date:  2000-08-28       Impact factor: 2.303

View more
  9 in total

1.  Highly enhanced cytotoxicity of a dimeric bispecific diabody, the hEx3 tetrabody.

Authors:  Ryutaro Asano; Keiko Ikoma; Yukiko Sone; Hiroko Kawaguchi; Shintaro Taki; Hiroki Hayashi; Takeshi Nakanishi; Mitsuo Umetsu; Yu Katayose; Michiaki Unno; Toshio Kudo; Izumi Kumagai
Journal:  J Biol Chem       Date:  2010-05-05       Impact factor: 5.157

2.  Cytotoxic enhancement of a bispecific diabody by format conversion to tandem single-chain variable fragment (taFv): the case of the hEx3 diabody.

Authors:  Ryutaro Asano; Keiko Ikoma; Ippei Shimomura; Shintaro Taki; Takeshi Nakanishi; Mitsuo Umetsu; Izumi Kumagai
Journal:  J Biol Chem       Date:  2010-11-19       Impact factor: 5.157

3.  Optimization of the crystallizability of a single-chain antibody fragment.

Authors:  Jana Škerlová; Vlastimil Král; Milan Fábry; Juraj Sedláček; Václav Veverka; Pavlína Rezáčová
Journal:  Acta Crystallogr F Struct Biol Commun       Date:  2014-11-14       Impact factor: 1.056

4.  A general chemical synthesis platform for crosslinking multivalent single chain variable fragments.

Authors:  Joan G Schellinger; Avinash Kudupudi; Arutselvan Natarajan; Wenjun Du; Sally J DeNardo; Jacquelyn Gervay-Hague
Journal:  Org Biomol Chem       Date:  2011-12-01       Impact factor: 3.876

5.  Sortase-catalyzed in vitro functionalization of a HER2-specific recombinant Fab for tumor targeting of the plant cytotoxin gelonin.

Authors:  Petra Kornberger; Arne Skerra
Journal:  MAbs       Date:  2013-12-09       Impact factor: 5.857

6.  Tumor targeting by a multivalent single-chain Fv (scFv) anti-Lewis Y antibody construct.

Authors:  Marcus P Kelly; F-T Lee; Kiki Tahtis; Barbara E Power; Fiona E Smyth; Martin W Brechbiel; Peter J Hudson; Andrew M Scott
Journal:  Cancer Biother Radiopharm       Date:  2008-08       Impact factor: 3.099

7.  Anti-EGFR scFv tetramer (tetrabody) with a stable monodisperse structure, strong anticancer effect, and a long in vivo half-life.

Authors:  Ryutaro Asano; Noriaki Koyama; Yasuyo Hagiwara; Yosuke Masakari; Ryota Orimo; Kyoko Arai; Hiromi Ogata; Shozo Furumoto; Mitsuo Umetsu; Izumi Kumagai
Journal:  FEBS Open Bio       Date:  2016-05-16       Impact factor: 2.693

8.  Systematic comparison of single-chain Fv antibody-fusion toxin constructs containing Pseudomonas Exotoxin A or saporin produced in different microbial expression systems.

Authors:  Pietro Della Cristina; Monica Castagna; Alessio Lombardi; Erika Barison; Giovanni Tagliabue; Aldo Ceriotti; Ilias Koutris; Luana Di Leandro; Francesco Giansanti; Riccardo Vago; Rodolfo Ippoliti; Sopsamorn U Flavell; David J Flavell; Marco Colombatti; Maria Serena Fabbrini
Journal:  Microb Cell Fact       Date:  2015-02-13       Impact factor: 6.352

9.  A novel synthetic trivalent single chain variable fragment (tri-scFv) construction platform based on the SpyTag/SpyCatcher protein ligase system.

Authors:  Md Kausar Alam; Michelle Brabant; Raja Solomon Viswas; Kris Barreto; Humphrey Fonge; C Ronald Geyer
Journal:  BMC Biotechnol       Date:  2018-09-10       Impact factor: 2.563

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.